Admission Date:  [**2143-11-1**]     Discharge Date:  [**2143-11-7**]  Date of Birth:   [**2085-9-26**]     Sex:  M  Service:  DIAGNOSIS: Metastatic renal cell carcinoma.
HISTORY OF PRESENT ILLNESS:  This is a 58-year-old male with metastatic renal cell carcinoma admitted for phase 1 and 2 trial of PEG-Intron with IL-2 for advanced renal cell carcinoma.
ONCOLOGIC HISTORY:  Patient initially presented with asymptomatic hematuria in [**2138**].
Biopsy revealed renal cell carcinoma and he underwent a radical nephrectomy.
He subsequently underwent resection of two lesions of the left posterior lung also consistent with renal cell carcinoma.
Serial CT scans in [**2143-9-16**] revealed a solitary left kidney mass of 2 cm and subsequently underwent a left partial nephrectomy.
A follow-up CT scan performed on [**2144-2-24**] showed evidence of increased metastatic disease with mediastinal lymphadenopathy, pulmonary nodules and increase size of the mass of lower pole of left kidney.
MRI confirmed the disease progression in the left kidney and pulmonary metastases.
He is currently enrolled in a phase [**12-18**] trial with outpatient PEG-Intron with IL-2 for advanced renal cell carcinoma.
PAST MEDICAL HISTORY:  Significant for hypertension.
ALLERGIES:  No known drug allergies.
FAMILY HISTORY:  Father died of an myocardial infarction.
Clear oropharynx, pink with exudate, no oral mucoid cutaneous lesions.
Neck:  No anterior, posterior cervical lymphadenopathy.
No supraclavicular axillary lymphadenopathy.
Heart:  Regular rate and rhythm, no murmurs, rubs or gallops.
Abdomen soft, nontender, nondistended, active bowel sounds, no hepatosplenomegaly.
Extremities:  No peripheral edema, no rashes.
He tolerated the two medications without incident.
He denied any nausea, vomiting or diarrhea.
He had no skin flushing.
He had no appreciable toxicities.
